B-Cell-Maturation-Antigen (BCMA) als Target in der Myelomtherapie

Jan Frenking; Lilli Sophie Sester; Marc-Steffen Raab

doi:10.1055/a-1981-0034

TumorDiagnostik & Therapie, Table of Contents

TumorDiagnostik & Therapie 2023; 44(04): 255-259
DOI: 10.1055/a-1981-0034

Übersicht

Schwerpunkt

B-Cell-Maturation-Antigen (BCMA) als Target in der Myelomtherapie

CAR-T-Zell-Therapie, Antikörper-Wirkstoff-Konjugate und bispezifische Antikörper

Jan Frenking

,

Lilli Sophie Sester

,

Marc-Steffen Raab

Abstract

Das Multiple Myelom ist durch wiederkehrende Rezidive und eine progrediente Therapierefraktärität gekennzeichnet. Neuartige Immuntherapien wie CAR-T-Zellen und bispezifische Antikörper werden die Behandlungslandschaft des Multiplen Myeloms revolutionieren. Die Effektivität und das Sicherheitsprofil dieser Therapien sind jedoch von der Spezifität der Zielstruktur abhängig. BCMA als therapeutischer Angriffspunkt stellt eine vielversprechende Option dar.

Schlüsselwörter

Multiples Myelom - BCMA - Antikörper-Wirkstoff-Konjugate - CAR-T-Zellen - bispezifische Antikörper

Full Text

References

Literatur
1 Cowan AJ. et al. Diagnosis and Management of Multiple Myeloma: A Review. JAMA 2022; 327: 464-477
2 Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Frontiers in Immunology 2018; 9
3 Lee L. et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol 2016; 174: 911-922
4 Carpenter RO. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013; 19: 2048-2060
5 Shah N, Chari A, Scott E. et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020; 34: 985-1005
6 Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 2015; 7: 1187-1199
7 Tai YT. et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 2016; 127: 3225-3236
8 Moreaux J. et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-3157
9 Lonial S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. The Lancet Oncology 2020; 21: 207-221
10 Kriegsmann K. et al. Cell-based immunotherapy approaches for multiple myeloma. Br J Cancer 2019; 120: 38-44
11 Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood 2017; 130: 2594-2602
12 Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J 2021; 11: 1-18
13 Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020; 20: 651-668
14 de Donk NWCJ, Themeli M, Usmani SZ. Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma. Blood Cancer Discovery 2021; 2: 302-318
15 Munshi NC. et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine 2021; 384: 705-716
16 Berdeja JG. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-324
17 Moreau P. et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine 2022; 387: 495-505
18 Dalovisio A. et al. P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. HemaSphere 2022; 6: 788-789
19 Pillarisetti K. et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv 2020; 4: 4538-4549
20 Alhallak K.. et al. Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. Cancers 2021; 13: 2853
21 Bahlis NJ. et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). JCO 2021; 39: 8006-8006
22 Holthof LC, Mutis T. Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance. Cancers (Basel) 2020; 12: 988
23 Zanwar S, Nandakumar B, Kumar S. Immune-based therapies in the management of multiple myeloma. Blood Cancer J 2020; 10: 84
24 Cohen AD. et al. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. Clinical Cancer Research 2020; 26: 1541-1554